Advances in the Diagnosis and Therapy of Double-hit Lymphoma--Review.
10.19746/j.cnki.issn.1009-2137.2019.04.052
- Author:
Xin-Xin WEI
1
;
Qing ZHAO
2
;
De-Peng LI
1
;
Yi-Hong HUANG
3
Author Information
1. Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Department of Hematology, Third Affiliated Hospital of Xuzhou Medical University, Xuzhou 221003, Jiangsu Province, China.
3. Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China Department of Hematology, Third Affiliated Hospital of Xuzhou Medical University, Xuzhou 221003, Jiangsu Province, China E-mail: hxr1583@sina.com.
- Publication Type:Journal Article
- MeSH:
Genetic Predisposition to Disease;
Humans;
Immunotherapy, Adoptive;
Lymphoma, B-Cell;
Proto-Oncogene Proteins c-bcl-2;
Proto-Oncogene Proteins c-bcl-6;
Proto-Oncogene Proteins c-myc
- From:
Journal of Experimental Hematology
2019;27(4):1311-1315
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Double-hit lymphoma (DHL) is a high-grade B-cell lymphoma with MYC and BCL-2/BCL-6 rearrangement, which is a invasive disease with a poor prognosis. FISH is the most important diagnostic method. There is no standard protocol for this disease yet. New therapeutic approaches including targeted therapy，checkpoint inhibitors and chimeric antigen receptor T-cell therapy are changing the paradigm of treatment for DHL. This review summarizes new developments in diagnosis and treatment of double-hit lymphoma.
